Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996040295 - MONOCLONAL ANTIBODY FRAGMENT TO HUMAN OVARIAN CANCERS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

What is claimed is:

1. An F(ab')2 fragment of the monoclonal antibody MX35.

2. A fragment according to claim 1 labeled with a detectable marker.

3. A fragment according to claim 2, wherein the detectable marker is radioactive.

4. A fragment according to claim 1 conjugated to a therapeutic agent.

5. A fragment according to claim 4, wherein the therapeutic agent is radioactive.

6. A method of detecting human ovarian cancer in a subject which comprises obtaining a suitable sample from the subject, contacting the suitable sample with an amount of the fragment of claim 2 effective to and under conditions permitting the fragment to form a complex with an antigen present on human ovarian cancer cells if present in the sample, and detecting any complexes so formed, thereby detecting human ovarian cancer in the subject.

7. A method according to claim 6, wherein detecting human ovarian cancer in the subject comprises detecting a micrometastatic tumor or micrometastatic tumors in the suitable sample obtained from the subject.

8. A method according to claim 7, wherein the suitable sample is obtained from the subject's peritoneal cavity.

9. A method according to claim 6, wherein detecting human ovarian cancer in the subject comprises detecting an epithelial ovarian carcinoma or epithelial ovarian carcinomas in the subject .

10. A method of treating human ovarian cancer in a subject which comprises administering to the subject an amount of the fragment of claim 3 or claim 4 effective to treat human ovarian cancer.

11. A method according to claim 10, wherein the human ovarian cancer cells comprise a micrometastatic tumor or micrometastatic tumors.

12. A method according to claim 11, wherein the human ovarian cancer cells are located in the subject's peritoneal cavity.

13. a method according to claim 12, wherein administration comprises administering the fragment into the subject's peritoneal cavity.

14. A method of detecting human ovarian cancer in a subject which comprises administering to the subject an amount of the fragment of claim 2 effective to and under conditions permitting the fragment to specifically form a complex with an antigen present on human ovarian cancer cells if present within the subject, and detecting the detectable marker labelling the antibody so complexed.

15. A method according to claim 14, wherein detecting human ovarian cancer in the subject comprises detecting a micrometastatic tumor or micrometastatic tumors in the subject.

16. A method according to claim 14, wherein the micrometastatic tumor or micrometastatic tumors are in the subject's peritoneal cavity.

17. A method according to claim 16, wherein administration comprises administering the fragment into the subject's peritoneal cavity.